Onco-Nephrology Symposium, 2022

CME

Advertisement

This hybrid (in-person or virtual) symposium will offer up-to-date information and insights from national and international experts in this constantly evolving subspecialty. This goal is to provide an opportunity for academicians and clinicians to have personal exchanges with experts.

On the agenda:

  • Novel Biomarkers of Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplant
  • The Spectrum of Renal Pathology Post-Hematopoietic Stem Cell Transplant
  • Rescue Therapies for AKI in Onco-Nephrology: Rasburicase, Glucarpidase, and Beyond
  • Immune Checkpoint Inhibitor-Associated Acute Kidney Injury
  • Immune Checkpoint Inhibitors and Solid Organ Transplants
  • Immune Checkpoint Inhibitors Debate: Biopsy vs No Biopsy, with Expert Discussants
  • Treatment of Hyponatremia in Cancer Patients: The Role of Vaptans and Urea
  • Drug Dosing/GFR Measurement in the Cancer Patient with Kidney Disease
  • Smoldering Myeloma and Monoclonal Gammopathies of Renal Significance
  • Latest Treatment of Kidney Cancer
7.25 AMA PRA Category 1 Credits™ - maximum

7.25 ABIM MOC points

Venue: The Inn at Longwood Medical

Date

September 30, 2022

Location

Boston, Massachusetts 02115, United States

Email

ceprograms@hms.harvard.edu

Website

cmeregistration.hms.harvard.edu/events/onco-nephrology-symposium-2022/event-summary-bd0d6b221b624eb9b37141a56815ba85.aspx/

Advertisement